Black Diamond’s Cancer Drug May Be a ‘Master Key,’ Street Says

(Bloomberg) -- After doubling from a January debut, Black Diamond Therapeutics Inc. is drawing rave reviews from all four banks that are now giving the stock research coverage.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.